Nama's AI scorecard currently rates BioCryst Pharmaceuticals Buy (5.9 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is BCRX's P/E ratio?

BioCryst Pharmaceuticals trades at a trailing price-to-earnings ratio of 7.9.

When does BCRX report earnings?

BioCryst Pharmaceuticals's next scheduled report is on Feb 25, 2027. Analysts expect EPS of $0.13.

What is the BCRX price target?

The median analyst price target from 11 analysts is $17.00, with a range of $11.00 – $32.00.

Is BCRX Shariah compliant?

Nama's AAOIFI-style screen reads BioCryst Pharmaceuticals as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

BioCryst Pharmaceuticals (BCRX)

Healthcare · Drug Manufacturers Specialty Generic · NASDAQ

BioCryst Pharmaceuticals (BCRX) is a Healthcare company in the Drug Manufacturers Specialty Generic industry. It has a market capitalization of $1.98B, a trailing price-to-earnings ratio of 7.9 and a free-cash-flow yield of 20.6%. Over the most recent reported fiscal year, revenue grew 94.1%. Nama's AI scorecard rates it Buy, 5.9 out of 10. On 12-month momentum it ranks in the middle band of its market.

AI scorecard

Buy · 5.9/10

Positive, at the low end of Buy. As of Nov 7, 2026.

Momentum

Middle · +19.5% over 12 months ex. last

Middle fifth of its market on the past year's move.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-61.5%

How far the last close sits under the highest price of the past five years.

Market cap	$1.98B
Trailing P/E	7.9
Price / book	—
Price / sales	2.1
FCF yield	20.6%
Dividend yield	—
Gross margin	97.8%
Operating margin	-33.3%
Net margin	-40.9%
Revenue growth (YoY)	+94.1%
Revenue growth (3-yr annual)	+47.8%
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	0.6
Exchange	NASDAQ
Sector	Healthcare
Industry	Drug Manufacturers Specialty Generic

BCRX earnings

Next report: Feb 25, 2027 (Q4 2026, EPS estimate $0.13). Beat the EPS estimate in 4 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 4, 2026	$0.27	$0.12	+125.0%	$180.29M
Q2 2026	Aug 5, 2026	$0.35	$0.24	+45.8%	$218.25M
Q1 2026	May 6, 2026	$0.14	$0.11	+27.3%	$156.41M
Q4 2025	Feb 26, 2026	$0.21	$0.07	+200.0%	$406.56M

BCRX analyst price target

Median target $17.00 from 11 analysts, ranging $11.00 – $32.00.

Drug Manufacturers Specialty Generic peers

Ticker	Company	Market cap	P/E
TAK	Takeda Pharmaceutical	$67.16B	42.0
TEVA	Teva Pharmaceutical Industries	$49.72B	18.0
HLN	Haleon	$40.17B	21.3
ZTS	Zoetis	$32.81B	12.0
UTHR	United Therapeutics	$23.94B	21.2
VTRS	Viatris	$22.87B	7.8
NBIX	Neurocrine Biosciences	$16.66B	16.5
ELAN	Elanco Animal Health	$12.86B	24.3

Explore live BCRX data on Nama Insights →

Recent Congressional trades

BioCryst Pharmaceuticals trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Gilbert Cisneros	House	Buy	$1,001 - $15,000	Sep 4, 2026
Gilbert Cisneros	House	Buy	$1,001 - $15,000	Dec 15, 2025
Josh Gottheimer	House	Buy	$1,001 - $15,000	Nov 11, 2023
Josh Gottheimer	House	Sell	$1,001 - $15,000	Oct 15, 2023

BCRX FAQ

Is BCRX a buy?: Nama's AI scorecard currently rates BioCryst Pharmaceuticals Buy (5.9 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is BCRX's P/E ratio?: BioCryst Pharmaceuticals trades at a trailing price-to-earnings ratio of 7.9.
When does BCRX report earnings?: BioCryst Pharmaceuticals's next scheduled report is on Feb 25, 2027. Analysts expect EPS of $0.13.
What is the BCRX price target?: The median analyst price target from 11 analysts is $17.00, with a range of $11.00 – $32.00.
Is BCRX Shariah compliant?: Nama's AAOIFI-style screen reads BioCryst Pharmaceuticals as Not Shariah Compliant. At least one of the three ratios or the industry test failed.